Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results [Yahoo! Finance]
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection [Yahoo! Finance]
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $13.00 price target on the stock.